SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is facing significant downward pressure as investors react to a dual miss on top and bottom-line earnings and a lack of clear forward guidance. The community is sharply divided, with some investors liquidating positions due to fading confidence in core brand sales, while others view the sell-off as an irrational overreaction and are aggressively adding to their holdings in anticipation of a long-term turnaround.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending after reporting record quarterly revenue that significantly exceeded analyst estimates, accompanied by improved gross margins and potential upward revisions to annual guidance. The stock is generating intense community discussion and high volume as investors monitor potential short covering, upcoming pipeline catalysts, and speculative buyout interest.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing significant volatility and negative investor sentiment heading into its earnings report, driven by persistent selling pressure and ongoing community comparisons to better-performing ad-tech peers. Shareholders are closely watching for signs of growth or a potential strategic pivot, while short-interest levels and the stock's recent underperformance relative to the broader market remain central points of debate.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened volatility and massive trading volume following a record-breaking earnings report that showed significant revenue growth and improved guidance. Investors are actively debating the potential for a short squeeze, given the stock's high short interest, while community discussions remain sharply divided between those anticipating a major breakout and those warning of a potential pump-and-dump scenario.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is facing extreme volatility after reporting a slight revenue miss and cautious forward guidance, triggering a massive sell-off despite the company's strong year-over-year growth and robust profit margins. The community is sharply divided, with bulls viewing the 20% price drop as an overreaction and a buying opportunity for a cash-flow-positive company, while bears argue that the stock's valuation was unsustainable and that slowing growth is a sign of long-term weakness.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors debate the impact of an unconfirmed short position reportedly opened by Michael Burry, which has triggered volatility and intense speculation regarding the firm's AI infrastructure fundamentals. Amidst these rumors, the community remains sharply divided between those bracing for a pullback and bulls who view the stock's recent price swings as a shakeout ahead of highly anticipated earnings.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors focus on the upcoming earnings call, specifically seeking clarity on the clinical status of the proprietary COVID-19-Influenza Combination vaccine and the commercial trajectory of the Matrix-M adjuvant platform. Community discussion is polarized between frustration over the lack of near-term partnership announcements and bullish conviction in the long-term value of the company's vaccine technology.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is surging toward 52-week highs following strong institutional inflows and positive analyst upgrades that highlight its successful execution in the ACA marketplace. The community is actively discussing the stock's impressive momentum and the potential for a continued run as investors rotate into high-growth healthcare names.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is experiencing heightened volatility following a major lockup expiration, with the community actively debating whether the stock's resilience against selloff pressure signals a bottom or if institutional selling will continue to dampen the rally. Investors remain polarized, with many analyzing the long-term potential of the company's AI infrastructure and space projects versus the immediate risks posed by ongoing share dilution.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid high anticipation for a potential Senate vote on the Clarity Act, with community sentiment deeply divided between long-term holders betting on institutional utility and skeptics citing stagnant price action. Investors are closely monitoring price support levels, waiting for regulatory news to determine if the asset will finally break out of its prolonged consolidation range.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher

PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript

PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April

PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest...

PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of PDS Biotechnology in a research note on Wednesday...

Why Is PDS Biotechnology Stock Gaining Wednesday?

PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.read more...

PDSB Stock Hits 37-Week High — Here’s The Latest On Its Therapy To Treat Metastatic Colorectal Cancer

Equity

The biotech firm said its Phase 2 trial of PDS01ADC showed a strong objective response rate and a 24-month survival rate.

PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

$PDSB Q1 '26 Earnings Results & Recap

Reported GAAP EPS of -$0.13 up 38.10% YoY

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

PDS Biotechnology Corporation

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.13	--	--	N/A
Q1 '26	-$0.14	-$0.13	7.14%	BEAT
Q4 '25	-$0.20	-$0.13	35.00%	BEAT
Q3 '25	-$0.20	-$0.19	3.39%	BEAT
Q2 '25	-$0.23	-$0.21	10.00%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings